Preoperative β-blocker use and mortality and morbidity following CABG surgery in North America

T. Bruce Ferguson, Laura P. Coombs, Eric D. Peterson

Research output: Contribution to journalArticlepeer-review

Abstract

Context β-Blockade therapy has recently been shown to convey a survival benefit in preoperative noncardiac vascular surgical settings. The effect of preoperative β-blocker therapy on coronary artery bypass graft surgery (CABG) outcomes has not been assessed. Objectives To examine patterns of use of preoperative β-blockers in patients undergoing isolated CABG and to determine whether use of β-blockers is associated with lower operative mortality and morbidity. Design, Setting, and Patients Observational study using the Society of Thoracic Surgeons National Adult Cardiac Surgery Database (NCD) to assess β-blocker use and outcomes among 629877 patients undergoing isolated CABG between 1996 and 1999 at 497 US and Canadian sites. Main Outcome Measure Influence of β-blockers on operative mortality, examined using both direct risk adjustment and a matched-pairs analysis based on propensity for preoperative β-blocker therapy. Results From 1996 to 1999, overall use of preoperative β-blockers increased from 50% to 60% in the NCD (P<.001 for time trend). Major predictors of use included recent myocardial infarction; hypertension; worse angina; younger age; better left ventricular systolic function; and absence of congestive heart failure, chronic lung disease, and diabetes. Patients who received β-blockers had lower mortality than those who did not (unadjusted 30-day mortality, 2.8% vs 3.4%; odds ratio [OR], 0.80; 95% confidence interval [CI], 0.78-0.82). Preoperative β-blocker use remained associated with slightly lower mortality after adjusting for patient risk and center effects using both risk adjustment (OR, 0.94; 95% CI, 0.91-0.97) and treatment propensity matching (OR, 0.97; 95% CI, 0.93-1.00). Procedural complications also tended to be lower among treated patients. This treatment advantage was seen among the majority of patient subgroups, including women; elderly persons; and those with chronic lung disease, diabetes, or moderately depressed ventricular function. Among patients with a left ventricular ejection fraction of less than 30%, however, preoperative β-blocker therapy was associated with a trend toward a higher mortality rate (OR, 1.13; 95% CI, 0.96-1.33; P=.23). Conclusions In this large North American observational analysis, preoperative β-blocker therapy was associated with a small but consistent survival benefit for patients undergoing CABG, except among patients with a left ventricular ejection fraction of less than 30%. This analysis further suggests that preoperative β-blocker therapy may be a useful process measure for CABG quality improvement assessment.

Original languageEnglish (US)
Pages (from-to)2221-2227
Number of pages7
JournalJournal of the American Medical Association
Volume287
Issue number17
DOIs
StatePublished - May 1 2002
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Preoperative β-blocker use and mortality and morbidity following CABG surgery in North America'. Together they form a unique fingerprint.

Cite this